drugset
drugset / Trial / NCT04694781

Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy

NCT04694781 ↗

Phase 1 Completed 18 enrolled Lyvgen Biopharma Holdings Limited
Non-randomizedSequentialOpen-labelTreatment

Summary

The study of LVGN6051-201 is designed to use a bridging dose escalation to quickly establish the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) as well as the recommended Phase 2 dose(s) (RP2D) of LVGN6051, both as a single agent (monotherapy) and in combination with a fixed dose of anti-PD-1 antibody (Pembrolizumab) in the treatment of advanced or metastatic malignancy.

Timeline

Start
2021-05-14
Primary completion
2023-10-31
Completion
2023-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject EXLINKIBART Monoclonal antibody — Intravenous
Background Pembrolizumab Monoclonal antibody — Intravenous

Indications

cancer